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Emerging Drug Therapies for 
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Abstract
The systemic chemotherapy combination of cisplatin and pemetrexed has 
been the mesothelioma standard of care for well over a decade. This regimen has 
only achieved a disappointing overall median survival of about 1 year. Improved 
survival has been reported when systemic chemotherapy is combined with surgery 
and radiotherapy, and for using localized chemotherapy in some cases. The choice 
of mesothelioma treatment often depends on the anatomical location, histologic 
subtype, and disease progression. Several experimental drugs have also been 
investigated in mesothelioma, often with limited positive results that maintain the 
reputation of mesothelioma as a graveyard for drug development. This chapter will 
review the use of drug treatment in mesothelioma and highlight emerging experi-
mental drug therapies in clinical trials. Experimental drugs for mesothelioma 
include inhibitors for checkpoints, epidermal growth factor, AXL, focal adhesion 
kinase, vascular endothelial growth factor, poly-ADP-ribose-polymerase, and 
hippo signaling.
Keywords: targeted drugs, experimental therapeutics, molecular therapies, drug 
combinations, NF2 mutations, BAP1 mutations
1. Introduction
The treatment of mesothelioma currently varies by primary origin of the tumor, 
histologic subtype, and disease progression. The most common mesothelioma is 
malignant pleural mesothelioma (about 80% of cases) [1]. Research for new drug 
treatments are often investigated in pleural mesothelioma and later extrapolated to 
less common types such as peritoneal mesothelioma (about 10% of cases). Both of 
these mesothelioma types have the same three subtypes of epithelioid, sarcomatoid, 
and biphasic histology. Biphasic mesothelioma is a combination of epithelioid 
and sarcomatoid histology, each contributing to at least 10% of the tissue [2]. 
Mesothelioma tends to spread regionally, then into the alternate thoracic lobe for 
pleural mesothelioma or across the abdomen for peritoneal mesothelioma, and can 
metastasize across the diaphragm or as distant metastases [2, 3]. Distant metastases 
were found in a postmortem study in over half of the 318 pleural mesothelioma 
patients examined, while distant metastasizes of peritoneal mesothelioma are not 
as common [2, 4]. Surgery is more common when disease is diagnosed early and 
tumors are resectable, but most patients are diagnosed at later stages of disease 
when they are not candidates. For pleural mesothelioma, extrapleural pneumonec-
tomy and pleurectomy/decortication are the most common nonpalliative proce-
dures for tumors that are confined to the excised region [5]. Some of these patients 
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will be treated with postoperative radiation and systemic chemotherapy, while the 
benefits of preoperative treatment are still being investigated. For epithelioid peri-
toneal mesothelioma, cytoreductive surgery is often combined with perioperative 
chemotherapy [2]. Cytoreductive surgery has been found to have minimal benefit 
for sarcomatoid and biphasic peritoneal mesothelioma, and systemic chemotherapy 
is often the first line treatment for these patients [6]. Treatment for relapsed 
and treatment-refractory mesothelioma is generally palliative or experimental. 
Currently, there are about 200 initiated and active clinical trials for mesothelioma 
listed at clinicaltrials.gov (U.S. National Library of Medicine), and the majority of 
these are drug-based interventions.
There are no targeted therapies currently approved for mesothelioma. Many 
ongoing research studies and clinical trials are investigating receptor tyrosine 
kinase inhibitors and checkpoint inhibitors of the immune system. Surprisingly, 
very few studies are being done that specifically target frequent genetic alterations 
in mesothelioma. In this review, we discuss the current chemotherapy and highlight 
emerging experimental drugs for mesothelioma treatment.
2. Systemic and localized chemotherapy
The current chemotherapy standard of care for mesothelioma is a systemic com-
bination of cisplatin and pemetrexed. Adding pemetrexed with cisplatin improved 
overall median survival of pleural mesothelioma patients from 9.3 months with 
cisplatin alone to 12.1 months for the combination, which was determined by a 
phase III clinical trial of the combination in 2003 [7]. Second-line treatments 
include cisplatin combined with gemcitabine or irinotecan [8–10], and vinorelbine 
monotherapy [11]. Depending on the disease progression, systemic chemotherapy 
is often combined with surgery or radiation. The prediction of which late-stage 
patients will benefit from surgery has proven to be difficult [5]. Radiotherapy 
alone has not been shown to improve overall survival, but this method is used in 
combination with surgery or systemic chemotherapy and for palliative purposes. 
Systemic cisplatin and pemetrexed therapy also remains the standard of care for 
peritoneal mesothelioma, and this regimen is often used for sarcomatoid and bipha-
sic histologic subtypes [6]. Combining gemcitabine with cisplatin was reported to 
achieve an overall median survival of about 27 months for patients with unresect-
able peritoneal mesothelioma, but this combination has also shown considerable 
toxicity [9]. Similar to several other abdominal cancers, many epithelioid peritoneal 
mesothelioma patients benefit from intraperitoneal chemotherapy administration.
Cytoreductive surgery followed by perioperative hyperthermic (or heated, 
hot) intraperitoneal chemotherapy for epithelial peritoneal mesothelioma patients 
(about 75% of peritoneal mesothelioma patients [2]) has extended overall median 
survival, which was reported as 53 months [12] and 38 months [13] in two separate 
multi-institutional studies. The drugs are heated to 42°C and administered to the 
peritoneal cavity for hours, often while rocking the patient to improve drug dis-
semination [2]. Intraperitoneal administration of chemotherapy gained attention in 
the 1980s when this route was shown to have a superior pharmacokinetic profile for 
cisplatin over intravenous injection in canines [14]. With intraperitoneal adminis-
tration, most of the chemotherapy remained in the peritoneal cavity and therefore 
much higher concentrations of drugs could be used, which were up to 30 times 
greater than common doses for intravenous injection [2, 15]. The effectiveness of 
hyperthermic intraperitoneal chemotherapy is based on the limits of drug penetra-
tion depth and correlates to the ability for achieving complete or near-complete 
cytoreduction [2, 16]. The drugs used are often varied combinations of cisplatin, 
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mitomycin-C, and doxirubicin [6]. A significant proportion of patients have also 
benefited from additional long-term normothermic intraperitoneal chemotherapy 
following the hyperthermic perioperative dosing [6].
Overall, the main chemotherapy drugs for mesothelioma have led to unsatisfac-
tory overall median survival percentages even when combined with radiation and 
surgical methods. Many mesothelioma patients try experimental drugs as part of 
clinical trials or compassionate-use programs. Unfortunately, mesothelioma has 
gained a reputation as a graveyard for drug development based on the minimal 
 successes and modest extensions of overall survival from experimental drugs. 
Clinical trials to evaluate targeted drugs in mesothelioma tumors with specific 
genetic alterations have only recently increased to a relatively small number.
3. Frequent genetic alterations
The most well-known and frequent genetic alterations in mesothelioma are 
mutations in BAP1, NF2, and TP53 genes and deletion of the CDKN2A gene. These 
mutations, along with mutations in LATS2 and SETD2, were reported as the most 
frequent in two independent sequencing studies of mesothelioma tissues [17, 18]. 
Activation of the LATS2 kinase is regulated by NF2, and the SET2D protein is an H3 
histone methyltransferase associated with tumor suppressor activity [19]. While the 
high frequency of some mutations in mesothelioma have been known for decades 
(e.g. NF2) and others have been discovered within the last decade (e.g. BAP1), there 
are still no targeted therapies approved for mesothelioma. Clinical trials requiring 
genetic testing for inclusion will be discussed in the next section.
Mutations in BAP1, the gene for the BRCA1-associated protein-1 deubiquitinating 
enzyme, were initially associated with mesothelioma as germline hereditary mutations 
[20], but it is now estimated that about 60% of mesothelioma tumors contain a muta-
tion in BAP1 (the majority being somatic acquired mutations) [5, 21–23]. It has been 
demonstrated that BAP1 regulates the DNA repair and apoptotic signaling in response 
to asbestos exposure [24, 25], which is the most common cause of mesothelioma. 
BAP1 loss also has been correlated to elevated trimethylation of H3 lysine 27 in mice, 
which recently lead to targeting the enhancer of zeste homolog 2 (EZH2) methyltrans-
ferase as a potential mesothelioma treatment strategy [26]. Germline BAP1 mutations 
have been found in over 200 families across the globe, and about a third of cancer 
diagnoses in carriers of BAP1 mutations are types of mesothelioma [5, 27]. BAP1-
negative mesothelioma tumors mainly consist of the epithelioid histologic subtype [5].
The most unique frequent mutations for mesothelioma are that of the NF2 gene. 
The NF2 gene encodes the merlin protein (also known as neurofibromin 2), which 
has tumor suppressor activity and is associated with cell cycle/growth control 
through the hippo pathway [28]. Canonical hippo signaling controls the yes-
associated protein (YAP), a transcription regulator for many cell cycle-associated 
genes. Verteporfin is a small molecule with YAP inhibitor activity that is approved 
for macular degeneration and has recently shown activity against in vitro mesothe-
lioma models [29, 30]. We have found that mesothelioma cells are very sensitive 
to the antimalarial drug quinacrine in vitro when inactivating NF2 mutations are 
present (unpublished data). While there are no clinical trials for mesothelioma 
involving these molecules, both of these drugs have potential to be repurposed for 
NF2-negative mesothelioma. Outside of mesothelioma, NF2 mutations are only 
frequently found in a few rare neurological cancers and the inherited neurofibro-
matosis type II syndrome. It is estimated that about 40% of mesothelioma tumors 
have NF2 mutations, although there are many other hippo-related genes found 
mutated in mesothelioma tumors at lower frequencies [31, 32].
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Inactivation of the TP53 and CDKN2A genes are not unique to mesothelioma, 
and these genes are known to be the first- and second-most common mutations in 
all cancer, respectively. The TP53 gene is only mutated in about 15% of mesothe-
lioma tumors [18], far below the TP53 mutation rate for most other cancer types. 
Deletion of the CDKN2A gene is found in about 45% of all mesothelioma tumors 
[18]. The CDKN2A (cyclin-dependent kinase inhibitor 2A) gene encodes for p14arf 
and p16INK4a tumor suppressor proteins that regulate cell cycle activities.
Mansfield and colleagues recently used mate-pair sequencing analyses to show 
most mesothelioma tumors contain several chromosomal rearrangements [33]. In 
22 mesothelioma patient samples examined, 13 samples contained CDKN2A dele-
tions and 14 samples had NF2 deletions. This suggests the genetics of mesothelioma 
cancer cells may be altered more than previously detected in several studies that 
used next generation sequencing methods.
4. Emerging molecular therapies
Pemetrexed was the last drug to be approved by the FDA for mesothelioma in 
2004, and now several novel molecular therapies which have had success in other 
cancers are now being tried in mesothelioma. Among the long list, angiogenesis 
inhibitors and immune checkpoint inhibitors have arguably made the most progress 
in clinical trials.
In a recent phase III clinical trial, the vascular endothelial growth factor (VEGF) 
inhibitor bevacizumab was added to cisplatin and pemetrexed combination therapy 
for patients with unresectable mesothelioma (Table 1, NCT00651456) [34]. This 
three-drug combination resulted in significant improvement for overall survival to 
18.8 months without a significant negative impact for health-related quality-of-life 
in patients with advanced pleural mesothelioma [35]. This combination has not 
yet been approved by the FDA. Another VEGF inhibitor, cediranib, was evaluated 
in combination with cisplatin and pemetrexed in a phase II trial for unresectable, 
chemotherapy naïve pleural mesothelioma (NCT01064648). This study reported 
improved progression-free survival and response rate, but further development 
has been halted based on the toxicity profile obtained during the trial [36]. Two 
other multitarget drugs that inhibit VEGF receptors, axitinib and nintedanib, did 
not meet clinical benefit goals when combined with cisplatin and pemetrexed [37]. 
Axitinib was unsuccessful when evaluated in a phase II trial for chemotherapy 
naïve, unresectable epithelioid pleural mesothelioma (NCT01211275). Combining 
nintedanib with pemetrexed and cisplatin did not meet the primary progression-
free survival goals in a phase III clinical trial for advanced pleural mesothelioma 
[38]. The European-based BEAT-mesophase III trial is in the early stages and adds 
atezolizumab to the cisplatin, pemetrexed, and bevacizumab combination for 
advanced pleural mesothelioma (NCT03762018). Atezolizumab is a monoclonal 
antibody against programmed cell death-ligand 1 (PD-L1). The MiST phase II trial 
also has an arm for evaluating atezolizumab and bevacizumab in relapsed mesothe-
lioma that has positive PD-L1 expression (NCT03654833). It is estimated that up to 
25% of mesothelioma patients may benefit from immune checkpoint inhibitors [5].
Interest in PD-L1 inhibitors for mesothelioma is based on prior success of these 
inhibitors in other cancer types and a study showing about 40% of the 212 mesothe-
lioma patient samples examined express PD-L1 [17]. It was also shown in the latter 
study that high PD-L1 expression correlated with poor survival for the mesotheli-
oma patients. In addition to the BEAT-meso clinical trial, atezolizumab is also being 
evaluated in a phase II trial on unresectable or advanced pleural mesothelioma 
(NCT03786419). The combination of PD-L1 inhibitor durvalumab with cisplatin 
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Study title Drug interventions Phase NCT number
Mesothelioma Avastin Plus Pemetrexed-
cisplatin Study*
Bevacizumab, 
pemetrexed, cisplatin
2/3 NCT00651456
Pemetrexed Disodium and Cisplatin 
With or Without Cediranib Maleate in 
Treating Patients With Malignant Pleural 
Mesothelioma
Cediranib, pemetrexed, 
cisplatin
2 NCT01064648
Standard Chemotherapy With or Without 
Axitinib in Malignant Mesothelioma 
(N08CPA)*
Axitinib, pemetrexed, 
cisplatin
2 NCT01211275
Nintedanib (BIBF 1120) in Mesothelioma** Nintedanib, 
pemetrexed, cisplatin
2/3 NCT01907100
Bevacizumab and Atezolizumab in Malignant 
Pleural Mesothelioma (BEAT-meso)
Bevacizumab, 
atezolizumab, cisplatin, 
pemetrexed
3 NCT03762018
Mesothelioma Stratified Therapy (MiST): 
A Multi-drug Phase II Trial in Malignant 
Mesothelioma
Bemcentinib & 
pembrolizumab, 
atezolizumab & 
bevacizumab, 
rucaparib, abemaciclib
2 NCT03654833
A Study of Atezolizumab in Unresectable or 
Advanced Malignant Pleural Mesothelioma
Atezolizumab 2 NCT03786419
Pembrolizumab in Patients With Advanced 
Malignant Pleural Mesothelioma
Pembrolizumab, 
pemetrexed, cisplatin
2/3 NCT02784171
CheckpOiNt Blockade For Inhibition of 
Relapsed Mesothelioma
Nivolumab 3 NCT03063450
Study of Nivolumab Combined With 
Ipilimumab Versus Pemetrexed and Cisplatin 
or Carboplatin as First Line Therapy in 
Unresectable Pleural Mesothelioma Patients
Nivolumab, 
ipilimumab, 
pemetrexed, cisplatin, 
carboplatin
3 NCT02899299
Randomized, Double-blind Study Comparing 
Tremelimumab to Placebo in Subjects With 
Unresectable Malignant Mesothelioma
Tremelimumab 2 NCT01843374
A Phase 2 Study of Durvalumab in 
Combination With Tremelimumab in 
Malignant Pleural Mesothelioma**
Tremelimumab, 
durvalumab
2 NCT03075527
Pembrolizumab + Defactinib In Pleural 
Mesothelioma
Pembrolizumab, 
defactinib
1 NCT04201145
Targeted Therapy Directed by Genetic 
Testing in Treating Patients With Advanced 
Refractory Solid Tumors, Lymphomas, or 
Multiple Myeloma (The MATCH Screening 
Trial)
Several targeted drugs 
including defactinib 
for tumors with NF2 
inactivating mutations
2 NCT02465060
Everolimus (RAD001) for the Treatment 
of Malignant Pleural Mesothelioma With 
Merlin/NF2 Loss as a Biomarker to Predict 
Sensitivity*
Everolimus 2 NCT01024946
Study of the EZH2 Inhibitor Tazemetostat in 
Malignant Mesothelioma*
Tazemetostat 2 NCT02860286
A Trial of Niraparib in BAP1 and Other 
DNA Damage Response (DDR) Deficient 
Neoplasms (UF-STO-ETI-001)
Niraparib 2 NCT03207347
Olaparib in People With Malignant 
Mesothelioma
Olaparib 2 NCT03531840
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and pemetrexed as a first-line treatment for unresectable pleural mesothelioma has 
also been reported to be advancing to a larger randomized phase III trial [5, 39]. 
Pembrolizumab is a PD-1 (which binds to PD-L1) inhibitor currently being used 
for a phase II/III trial (NCT02784171) for advanced pleural mesothelioma both as a 
monotherapy (phase II) and in combination with cisplatin and pemetrexed (phase 
III). Nivolumab is a PD-1 inhibitor in two phase III clinical trials, which are for 
relapsed mesothelioma (NCT03063450) and as a first-line treatment when com-
bined with ipilimumab for unresectable pleural mesothelioma (NCT02899299). 
Ipilimumab is a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor 
that has showed encouraging results when previously combined with nivolumab 
in two separate phase II trials for mesothelioma [40, 41]. The CTLA-4 inhibitor 
tremelimumab was reported to be unsuccessful as a second-line treatment in two 
phase II clinical trials. As a monotherapy, it did not prolong overall survival for both 
unresectable pleural and peritoneal mesothelioma (NCT01843374) [42] and the 
primary endpoint for overall response rate was not met when tested in combination 
with durvalumab for pleural mesothelioma (NCT03075527) [43].
The PD-1 inhibitor pembrolizumab is also being combined with the focal adhe-
sion kinase inhibitor defactinib in a phase 1 clinical trial (NCT04201145). There had 
previously been a lot of interest in the ability of focal adhesion kinase inhibition to 
selectively eliminate mesothelioma cells, but enthusiasm significantly decreased 
after defactinib failed to improve progression-free and overall survival in prior 
mesothelioma clinical trials (NCT02004028, NCT01870609) [44]. However, defac-
tinib is now also in the MATCH screening phase II trial for patients with advanced 
refractory solid tumors containing NF2 inactivating mutations as a second-line treat-
ment (NCT02465060, subprotocol U). This is the only current clinical trial (to the 
best of our knowledge) that may potentially address inactivating NF2 mutations 
in mesothelioma (note that the trial is not specific to mesothelioma and does not 
guarantee mesothelioma patient enrollment). The mTOR inhibitor everolimus had 
been previously studied in a second-line mesothelioma phase II trial that also evalu-
ated NF2 loss as a biomarker of sensitivity (NCT01024946), but this trial resulted 
in limited clinical activity and everolimus did not progress as a monotherapy agent 
for mesothelioma [45]. In preclinical studies, we have found that repurposing the 
antimalarial drug quinacrine may be particularly effective against cells with inacti-
vating NF2 mutations by disrupting hippo signaling (unpublished data). Quinacrine 
is unique as an anticancer agent in that it has an excellent safety profile from almost 
a century of use for malaria prophylaxis/treatment [46]. Further mechanistic 
and clinical studies are needed to fully understand the potential of quinacrine for 
mesothelioma treatment. Moreover, verteporfin has also been preclinically evalu-
ated as a YAP inhibitor for mesothelioma, but has not progressed to clinical trials 
yet [29, 30]. To address BAP1 inactivation, a phase II trial testing the EZH2 inhibitor 
tazemetostat with relapsed/refractory mesothelioma patients as a monotherapy 
(NCT02860286) recently concluded with encouraging preliminary data, specifically 
Study title Drug interventions Phase NCT number
Anti-Mesothelin Immunotoxin LMB-100 
Followed by Pembrolizumab in Malignant 
Mesothelioma
LMB-100, 
Pembrolizumab
2 NCT03644550
*Completed.
**Suspended/terminated.
Table 1. 
Highlighted drug-based clinical trials for mesothelioma from clinicaltrials.gov (U.S. National Library of 
Medicine).
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benefiting long-term disease control [47]. Targeting BAP1-mutated mesothelioma 
tumors with poly-ADP-ribose-polymerase (PARP) inhibitors has been promising 
based on preclinical studies [48, 49]. The PARP inhibitor niraparib is being evaluated 
as a second-line treatment in a phase II trial for tumors with DNA damage response 
mutations including BAP1 (NCT03207347). More recently, a phase II trial to evaluate 
the PARP inhibitor olaparib as a second-line treatment specifically for mesothelioma 
has started with arms to include BAP1 somatic mutations and germline DNA dam-
age repair mutations (NCT03531840). The MiST phase II trial also has an arm for 
investigating the PARP inhibitor rucaparib in BRCA1/BAP1-negative mesothelioma 
patients. Furthermore, the MiST trial has a third arm to study the CDK4/6 inhibitor 
abemaciclib for mesothelioma patients with p16INK4A negative (CDKN2A deletion) 
tumors. The fourth MiST arm evaluates AXL inhibitor bemcentinib in combination 
with pembrolizumab for relapsed mesothelioma patients without specific biomarker 
requirements. We have previously shown that AXL has relatively high expression 
in pleural mesothelioma compared to other cancer types, and that bemcentinib can 
selectively kill mesothelioma cells [50]. In pleural mesothelioma, a phase II trial with 
epidermal growth factor receptor (EGFR) inhibitor gefitinib was not successful [51]. 
However, peritoneal mesothelioma often has higher EGFR expression compared to 
pleural mesothelioma and may benefit from EGFR inhibitor therapy pending more 
clinical studies that are specific for this indication [2, 52].
Mesothelin and other biomarkers of mesothelioma have gained recent inter-
est as targets for immunotoxins and chimeric antigen receptor-T (CAR-T) cells. 
Mesothelin has been used for diagnostic purposes in algorithms with other bio-
markers as well as occasionally used for tumor surveillance [2, 5]. As a therapy 
target, the immunotoxin LMB-100 has been recently developed to bind mesothelin 
[53]. In 2018, a phase II trial started with LMB-100 followed by pembrolizumab for 
pleural and peritoneal mesothelioma cohorts (NCT03644550). CAR-T cells are also 
being developed to target mesothelin as a potential mesothelioma treatment [54].
5. Conclusions
Most mesothelioma patients have chemotherapy or experimental drugs as a 
major part of their treatment plan, but there have been very few highlights and 
minimal significant advancements for mesothelioma drugs over the last couple 
decades. Targeting specific types and characteristics of mesothelioma may have the 
most potential in the near future. It is surprising that targeted drugs as a whole have 
not progressed to end stages already either because of slower development pipelines 
or failure to hit endpoints for mesothelioma. There may also be an orphan drug clout 
that prevents development of drugs to target tumors with BAP1 and NF2 mutations. 
Proteomic characteristics of mesothelioma, specifically biomarkers currently used 
for diagnostic and tumor surveillance purposes, may also prove useful for novel 
chimeric therapies (e.g. protac and chimeric antigen receptor T cells), which are 
currently being developed for mesothelin. These and emerging targeted drugs such 
as AXL inhibitors, EGFR inhibitors for peritoneal mesothelioma, PARP inhibitors 
for BAP1-mutated tumors, and quinacrine for NF2-mutated tumors all have poten-
tial to finally kill the reputation of mesothelioma as a drug development graveyard.
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